Synexus expands Polish presence
The unit will increase capacity from one hundred to three hundred square meters and will enable the firm to hire additional four full time investigators.
Dr Radoslow Janiak, Synexus’ Poland manager explained that: “We are able to recruit the right number of patients within the right time frame and that’s exactly what sponsors are looking for.
“We are seeing considerable interest from a number of leading pharmas and CROs who are keen on the developments we have underway to increase our capacity here” continued Janiak.
Synexus’ CEO Michael Fort echoed these thoughts, commenting that “We are continuing to see increased levels of interest for clinical trials throughout the CEE, not least in Poland where our sites are very well located.”
“The pharma companies and CROs we are talking to continue to express their enthusiasm for increased capacity across the CEE and we are keen to help meet their demands.”
Synexus has operated in the country since 2006, with its first site in Wroclaw. It expanded operations in 2009 with the acquisition of three research centres in Warsaw, Gdynia and Katowice.
CEE a rapidly emerging market
With a population of more than 300 million, Central and Eastern Europe (CEE) offers great opportunities for the clinical trials industry, which has grown considerably in the region in recent years.
Synexus, for example, in addition to its sites in Poland, has facilities in Bulgaria, Hungary, Austria and Ukraine and recently acquired Clinpharm to further expand its reach.
The consensus opinion is that recruiting in these countries is a more rapid process than elsewhere and the patient population is treatment naïve. These factors, together with the growing number of qualified professional trial staff, make the CEE an attractive region for research.
